Shots:
- Otsuka reported the ongoing P-III (VISIONARY) trial data assessing Voyxact (sibeprenlimab; n= 320) vs PBO (n=152) in preserving kidney function in IgAN pts over a 24mos. treatment period
- At 12mos., Voyxactimproved kidney function with a mean eGFR change from baseline of +0.7 vs -4.8 mL/min/1.73 m², achieving the KDIGO treatment goal of limiting annual kidney function decline to the normal physiological rate (<1 mL/min/1.73m²/year)
- Voyxactalsodemonstrated a slower annualized eGFR decline over 12mos., with annualized slope of eGFR showing -3.0 vs -7.6mL/min/1.73 m²/year; data was presented at the ERA’26
Ref: Businesswire | Image: Otsuka | Press Release
Related News: Otsuka to Acquire Transcend Therapeutics for ~$1.225B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
